Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

C athie Wood's ARK ETFs published their daily trades for Friday, January 31st, 2025, with a notable emphasis on the biotech sector. Leading the charge in purchases was CRISPR Therapeutics AG ...

ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Susquehanna Fundamental Investments LLC bought a new position in CRISPR Therapeutics during the fourth quarter valued at $3,636,000. Virtus ETF Advisers LLC grew its holdings in CRISPR ...

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ... strategy is pretty straightforward: her ARK ETFs invest in developing high-tech firms in artificial ...

Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics CRSP. And retail traders should know. We noticed this today when the trades showed up on publicly ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...